Mizuho Rates Sol-Gel Technologies (SLGL) buy, $285 Price Target
Mizuho reaffirmed its buy rating for Sol-Gel Technologies Ltd. with a $285 price target, a 292.18% upside from the current price.
Reviewed by automated data checks against the source data. How we make and check alerts
Mizuho rated Sol-Gel Technologies Ltd. ($SLGL) "buy" with a $285 price target on June 24, 2026.
Since the rating, $SLGL is down 1.9% after 1 week, up 11.7% after 1 month and down 12.5% to date (from the $73.40 close on Jun 24, 2026).
SLGL
Sol-Gel Technologies Ltd.
Key Points
- Mizuho reiterated its buy rating for Sol-Gel Technologies Ltd. (SLGL) on June 24, 2026, with a $285 price target.
- Mizuho's $285 price target implies 292.18% upside from Sol-Gel Technologies Ltd.'s ($SLGL) current $72.67 share price.
- Shares of SLGL were trading at $73.4 on Friday, with a market cap of approximately $237.6 million.
- Opaleye Management Inc. and Citadel Advisors LLC adjusted their positions in Sol-Gel, with Citadel increasing by 49.9%.
Get $SLGL trade alerts by text
We text you when insiders, Congress or big funds trade $SLGL. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Sol-Gel Technologies Ltd. alert may contain errors. Disclosures
Mizuho has reiterated its buy rating for Sol-Gel Technologies Ltd. (NasdaqCM: SLGL) with a price target of $285. This announcement was made on June 24, 2026, by analyst Uy Ear. Shares of Sol-Gel traded at $73.4 on Friday.
Mizuho vs. the S&P 500
Hypothetical returns from Mizuho's disclosed trades, not real profit or advice. How we model this.
Other Institutional Activity in Sol-Gel Technologies Ltd.
Various institutions have been adjusting their holdings in Sol-Gel Technologies. Opaleye Management Inc. increased its stake by 46,261 shares, ending with 500,000 shares valued at approximately $39.6 million, representing a 10.2% increase. Great Point Partners LLC opened a new position with 274,363 shares worth about $21.7 million. Phoenix Financial Ltd. trimmed its stake by 7,366 shares, leaving it with 210,849 shares valued at around $16.7 million, a decrease of 3.4%. Citadel Advisors LLC significantly boosted its holdings, adding 30,946 shares for a total of 37,145 shares valued at $2.9 million, marking a 499.2% increase.
Sol-Gel Technologies Ltd. Stock Up 21.1%
On Friday, shares of Sol-Gel Technologies Ltd. (NasdaqCM: SLGL) traded near $73.4. The company has a market capitalization of roughly $237.6 million. Sol-Gel's forward P/E ratio isn't meaningful as the company is not currently profitable. The stock has seen a 52-week low of $6.96 and a high of $97.97, with a 50-day moving average of $72.96 and a 200-day moving average of $58.16. Sol-Gel has a beta of 1.127, indicating its stock is slightly more volatile than the market. The company maintains a strong liquidity position with a current ratio of 8.837 and a quick ratio of 8.537.
$SLGL price target
Sol-Gel Technologies Ltd. daily closes and this analyst's $285 target. Not advice.
Recent Earnings
Sol-Gel Technologies reported revenue of $18.5 million, though it experienced a revenue decline of 89.5%. The company posted a negative net margin of 5.7% and a return on equity of -2.9%. The next earnings release is expected on May 28, 2026.
Insider Buying and Selling at Sol-Gel Technologies Ltd.
Insider transactions at Sol-Gel Technologies include several buys by Opaleye Management Inc., such as 1,563 shares at $64.43 on May 20, 2026, and 1,937 shares at $66.87 on May 13, 2026. Additionally, Yosef Itzik sold 1,556 shares at $87.63 on February 25, 2026, under a planned sale.
Analysts Set New Price Targets
On June 24, 2026, Mizuho initiated coverage with a buy rating and a $285 price target. HC Wainwright & Co. also maintained its buy rating earlier this year with a target of $110. The consensus among analysts is a strong buy, with a mean target price of $193 based on three analyst opinions.
About Sol-Gel Technologies Ltd.
Sol-Gel Technologies Ltd. is a biotechnology company based in Ness Ziona, Israel, focusing on developing topical dermatological drugs. It offers products like Twyneo for acne and Epsolay for rosacea. The company is also working on treatments for Gorlin Syndrome and Olmsted Syndrome. Led by CEO Mr. Moshe Arkin, Sol-Gel collaborates with various pharmaceutical companies and operates internationally.
Bottom Line
Mizuho's reiterated buy rating and $285 price target underscore confidence in Sol-Gel Technologies Ltd.'s potential. Investors often track such analyst ratings for insights into a company's future prospects. It's important to remember that these ratings reflect analysts' views at the time of the report and may not predict future stock performance.
Related Filing Alerts
Source: Mizuho's rating change on $SLGL (Jun 24, 2026). Written by software, not financial advice. How we make alerts